Aug 25, 2025
Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright
Aug 15, 2025
Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis
Apr 16, 2025
Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th
Mar 19, 2025
Precigen Reports Full Year 2024 Financial Results and Business Updates
Feb 25, 2025
FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025
Dec 30, 2024
Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis
Dec 27, 2024
Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock
Aug 07, 2024
Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock
Jun 03, 2024
Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response
May 23, 2024
Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting
Apr 24, 2024
Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting
Mar 12, 2024
Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
Mar 05, 2024
Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th
Feb 04, 2021
Precigen to Participate in Guggenheim Healthcare Talks Oncology Day
Jan 22, 2021
Precigen Announces Pricing of $112.5 Million Public Offering of Common Stock
Jan 13, 2021
Precigen Provides Pipeline Updates at the 39th Annual J.P. Morgan Healthcare Conference
Jan 06, 2021
Precigen to Present at the 39th Annual J.P. Morgan Healthcare Conference
Dec 08, 2020
Precigen to Host R&D Update Virtual Event on December 15th to Share Latest Clinical Developments
Nov 16, 2020
Precigen Announces Dosing of First Patients with UltraCAR-T® Cells Manufactured Using Proprietary UltraPorator(TM) System in Ongoing PRGN-3005 and PRGN-3006 Phase 1 Clinical Trials
Nov 02, 2020
Precigen to Announce Third Quarter 2020 Financial Results on November 9th: Will host Pipeline and Data Update Call in Early December